1. Home
  2. OFS vs XLO Comparison

OFS vs XLO Comparison

Compare OFS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$3.86

Market Cap

54.3M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$8.93

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OFS
XLO
Founded
2001
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
56.9M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
OFS
XLO
Price
$3.86
$8.93
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
46.1K
9.5K
Earning Date
04-30-2026
05-14-2026
Dividend Yield
16.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$2.72
$0.46
52 Week High
$8.99
$9.90

Technical Indicators

Market Signals
Indicator
OFS
XLO
Relative Strength Index (RSI) 57.69 48.51
Support Level $3.26 $8.52
Resistance Level $4.06 $9.15
Average True Range (ATR) 0.16 0.29
MACD 0.02 -0.02
Stochastic Oscillator 70.45 57.33

Price Performance

Historical Comparison
OFS
XLO

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: